Ubiquitination/ Proteasome


Once the substrate protein is labeled, proteasome will bind to a polyubiquitin chain, allowing the degradation of the labeled protein. The polyubiquitinated target protein is then recognized and degraded by the 26S proteasome. Deubiquitinating enzymes (DUBs) reverse the process of ubiquitination by removing ubiquitin from its substrate protein. Dysregulation of the ubiquitin-proteasome system has been linked to cancer, diabetes, cardiovascular and neurodegenerative diseases etc.
-
A8633 Concanamycin A9 CitationTarget: Vacuolar-type ATPaseSummary: V-type (vacuolar) H+-ATPase inhibitor -
A8661 MNSSummary: Inhibitor of Src/Syk tyrosine kinases -
A8813 NSC697923Target: Ub-conjugating enzyme (E2) complexSummary: Inhibitor of E2 complex Ubc13-Uev1A,cell permeable and selective -
B1492 PYR-412 CitationTarget: ProteasomeSummary: inhibitor of Ubiquitin-Activating Enzyme (E1) -
B2168 NMS-8733 CitationTarget: Valosin-containing protein (VCP)Summary: VCP/p97 inhibitor,selective and allosteric -
A8172 Dihydroeponemycin1 CitationSummary: Proteasome inhibitor,antitumor reagent,eponemycin ddrivative -
BA2731 IberdomideSummary: Iberdomide (CC-220) is an orally effective (CRBN) E3 ligase modulator. -
BA2820 HinokiflavoneSummary: Hinokiflavone, a novel modulator of splicing activity, is effective in vitro and in vivo. -
BA2848 Wu-5Summary: Wu-5 is a USP10 inhibitor. -
BA2868 TZ9Summary: TZ9 is a selective inhibitor.

